Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

This publication has 17 references indexed in Scilit:

• Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
  Journal of Clinical Oncology, 2012
• Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
  Annals of Oncology, 2011
• Abiraterone and Increased Survival in Metastatic Prostate Cancer
  New England Journal of Medicine, 2011
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
  The Lancet, 2010
• Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
  New England Journal of Medicine, 2010
• The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
  European Journal of Cancer, 2010
• Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
  Journal of Clinical Oncology, 2008
• Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
  Journal of Clinical Oncology, 2008
• Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer
  Journal of Clinical Oncology, 2007
• Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16
  JNCI: Journal of the National Cancer Institute, 2006